[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wearable-devices\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wearable-devices":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,98,131,158,189,228],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100648378","wearable-blood-pressure-monitoring-comparison-study-100648378",false,"NCT07719660","Wearable Blood-Pressure Monitoring Comparison Study","Wearable Blood-Pressure Monitoring Comparison Study (WBPMCS)","WBPMCS","Inclusion Criteria:\n\n* Blood pressure measurements can be performed on at least one arm, for example no amputation, dialysis shunt, or obstructive dressing\n* Ability to understand the study information and provide written informed consent\n* For participants in the intensive care unit: an arterial line placed for clinical reasons\n\nExclusion Criteria:\n\n* Wrist circumference exceeds the size range of the investigated wearable devices\n* Physical or medical conditions preventing placement of the wearable devices, including relevant skin lesions, wounds, severe edema, or patient restraint\n* Inability to provide written informed consent",true,"ALL","21 Years","85 Years",{"count":22,"type":23},120,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to compare the accuracy, clinical applicability, and usability of different wearable blood pressure monitoring methods integrated in wearable devices, such as smartwatches, in hospitalized patients. The study evaluates novel photoplethysmography (PPG)-based and wrist-oscillometric blood pressure measurement methods against established clinical reference methods (upper-arm cuff measurements on the general ward and invasive arterial blood pressure monitoring (A-line) in the intensive care unit).\n\nThe main questions the study aims to answer are:\n\n* Can novel blood pressure monitoring methods suitable for integration into wearable devices achieve clinically acceptable agreement with established reference measurements?\n* How does the performance of calibration-dependent wearable devices change over time following calibration?\n* How does the performance of the investigated methods compare with each other?\n* How do the investigated methods perform for patients with different pre-existing conditions ?\n\nTo answer these questions, participants will undergo:\n\n* blood pressure measurements using different wearable devices based on PPG and wrist oscillometry\n* standardized reference blood pressure measurements using an upper-arm cuff (general ward) or an existing invasive arterial line (intensive care unit)\n* repeated measurements over three consecutive days on the general ward to assess calibration stability and measurement reproducibility,",[27,28,29,30,31],"Hypertension","Blood Pressure Monitoring","Wearable Devices","Photoplethysmography","Cuff","NOT_YET_RECRUITING","2026-07-22",{"date":35,"type":36},"2026-07-23","ACTUAL",{"date":38,"type":23},"2026-07-20",{"date":40,"type":23},"2027-12-31",{"name":42,"class":43},"Technische Universität Dresden","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":55,"conditions":56,"keywords":66,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100646258","continuous-vital-sign-monitoring-in-a-surgical-ward-100646258","NCT07690267","Continuous Vital Sign Monitoring in a Surgical Ward","Continuous Vital Sign Monitoring in a Norwegian Hospital Surgical Ward: A Multi-Method Study of Patient Outcomes, Patient Safety Culture, and Nursing Staff Experiences","Inclusion Criteria:\n\n* Patients aged 18 years or older admitted to the gastro-surgical ward.\n* Healthcare professionals aged 18 years or older employed in the participating wards for survey participation.\n* Nursing staff with at least 6 months of work experience and experience using CVSM for participation in qualitative focus group interviews.\n\nExclusion Criteria:\n\n* Patients with delirium.\n* Patients with cognitive impairment interfering with sensor use.\n* Patients who decline participation.\n* Patients with allergy to electrode adhesives.","18 Years",{"count":54,"type":23},9600,"Unsafe patient care remains a major contributor to global morbidity and mortality. In surgical wards, postoperative patients are typically monitored intermittently using the National Early Warning Score (NEWS-2), leaving periods during which clinical deterioration may go undetected. Continuous vital sign monitoring (CVSM) using wearable sensors offers the potential for earlier identification of deterioration compared with intermittent assessments.\n\nCVSM was introduced in a hospital ward as part of a hospital-initiated pilot implementation and is used alongside standard monitoring with NEWS-2. The purpose of the study is to evaluate this implementation.\n\nThis observational study uses a pragmatic, quasi-experimental, multi-method, longitudinal design. The overall aims of the study are to evaluate the impact of CVSM implementation on patient outcomes, to explore healthcare professionals' perceptions of patient safety culture, turnover intention and pleasure of work, and to describe their experiences with implementation.",[57,29,58,59,60,61,62,63,64,65],"Patient Monitoring","Telemonitoring","Patient Safety","Patient Deterioration","Nurses","Healthcare Professionals","Work-related Outcomes","Implementation","Implementation Research",[67,68,69,58,70,71,72,73,61,74,75,76,77,78,64,79,80,81,82,83,84,85,86],"Continuous vital sign monitoring","Patient monitoring","Wearable devices","Patient safety","Patient deterioration","Early warning scores","National Early Warning Score (NEWS-2)","Healthcare professionals","Patient safety culture","Hospital Survey on Patient Safety Culture (HSOPSC 2.0)","Employee motivation","Work-related outcomes","Technology implementation","Quasi-experimental design","Focus group interview","qualitative study","SEIPS","Digital health","Gastro-surgical ward","Postoperative patients","RECRUITING","2026-07-08",{"date":90,"type":36},"2026-07-09",{"date":92,"type":36},"2025-09-01",{"date":94,"type":23},"2026-10-01",{"name":96,"class":43},"University Hospital, Akershus",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":121,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":97},"100646888","effectiveness-of-supervised-and-unsupervised-mhealth-based-exercise-interventions-on-clinical-outcomes-in-adults-with-type-2-diabetes-and-obesity-within-a-primary-care-context-100646888","NCT07685080","\"Effectiveness of Supervised and Unsupervised mHealth-based Exercise Interventions on Clinical Outcomes in Adults With Type 2 Diabetes and Obesity Within a Primary Care Context\"","Effectiveness of Supervised and Unsupervised mHealth-based Exercise Interventions on Clinical Outcomes in Adults With Type 2 Diabetes and Obesity Within a Primary Care Context: a Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n* Diagnosed with both type 2 diabetes mellitus and obesity\n* Aged between 30 and 65 years\n* Body Mass Index (BMI) between 30 and 40 kg\u002Fm²\n* Glycated hemoglobin (HbA1c) greater than 6.5% (48 mmol\u002Fmol)\n* Fasting plasma or capillary blood glucose equal to or greater than 126 mg\u002FdL (7.0 mmol\u002FL)\n* Willing and able to provide informed consent to participate in the study\n* Available and willing to commit to a 20-week intervention period\n* Able and willing to use a smartphone and receive text messages\n* Able and willing to use a wearable device (smartwatch) and its associated mobile application\n\nExclusion Criteria:\n\n* Presence of any obesity-related comorbidity requiring clinical referral, including eating disorders, pseudotumor cerebri, sleep apnea, hypoventilation syndrome, or orthopedic problems that limit physical activity\n* Presence of psychiatric or medical conditions that would prevent compliance with the study protocol\n* History of a cardiovascular event (myocardial infarction, stroke, heart failure episode, or revascularization procedure) in the past 6 months\n* Presence of any medical condition that contraindicates participation in the proposed physical activity program\n* Current use of insulin therapy\n* Presence of orthopedic or other physical limitations that may interfere with the ability to exercise safely\n* Currently undergoing treatment for a malignant tumor (other than non-melanoma skin cancer)\n* Currently receiving treatment for, or diagnosed with, an eating disorder\n* Planned bariatric or weight-loss surgery (e.g., liposuction, gastric band, gastric bypass) within the next 5 months\n* Currently pregnant, given birth in the last 6 months, breastfeeding in the last 3 months, or actively planning a pregnancy in the next 5 months\n* Currently enrolled in, or planning to enroll in, a weight loss program during the study period\n* Lost more than 5 kilograms of body weight in the past 3 months","30 Years","65 Years",{"count":108,"type":23},126,"INTERVENTIONAL",[111],"NA","Type 2 diabetes (T2D) and obesity are two of the most common chronic conditions worldwide, and they frequently occur together. Both conditions are closely linked to physical inactivity, which is currently recognized as a major risk factor for a wide range of diseases. Although structured exercise programs have shown benefits for people living with these conditions, maintaining long-term participation remains a significant challenge. The rise of mobile health (mHealth) technologies - such as smartphone apps and wearable devices - offers a promising new way to support people in becoming and staying more physically active.\n\nThis study aims to compare the effects of two different 20-week exercise intervention programs versus standard medical care in adults aged 30 to 65 who have been diagnosed with both T2D and obesity.\n\nParticipants will be randomly assigned to one of three groups:\n\nGroup 1 (Supervised Training): Participants will attend two in-person, supervised exercise sessions per week at a local sports facility, each lasting 60 minutes. Sessions will be led by a qualified trainer and will include strength, flexibility, and functional exercises. Participants will also receive weekly motivational text messages and group health coaching.\n\nGroup 2 (Unsupervised mHealth Training): Participants will follow the same exercise plan independently using a mobile application (ActiVital), which is part of the Andalusian Physical Activity Prescription Plan (PAPEF). They will receive their weekly training schedule through the app and will also receive text messages and group health coaching.\n\nGroup 3 (Control Group): Participants will continue with their usual medical care without any structured exercise program.\n\nAll participants across the three groups will be provided with a Fitbit Charge 6 wearable device to monitor daily physical activity and health indicators.\n\nThe study's central hypothesis is that both structured supervised exercise and app-guided unsupervised exercise will lead to meaningful improvements in clinical indicators - such as blood glucose levels, glycated hemoglobin (HbA1c), blood lipids, and blood pressure - as well as in body composition, physical fitness, sleep quality, and overall quality of life, when compared to standard care alone. It is also hypothesized that the mHealth approach will show particular benefits in terms of adherence, self-management, and scalability.\n\nA total of 126 participants will be recruited through the Primary Care Center of Osuna (Seville, Spain), with measurements taken before and after the 20-week intervention period. The study will help determine which type of exercise program is most effective and feasible for people managing both type 2 diabetes and obesity in a primary care setting.",[114,115,116,117,118,119,120,29],"Diabetes Mellitus, Type 2","Obesity","Insulin Resistance","Sedentary Behaviors","mHealth","Physical Exercise","Primary Care",[114,115,118,122,119],"Wearable","2026-07-02",{"date":125,"type":36},"2026-07-06",{"date":94,"type":23},{"date":128,"type":23},"2027-04-01",{"name":130,"class":43},"Escuela Universitaria de Osuna",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100625558","physiological-benefits-from-the-removal-of-tracheostomy-tubes-obtained-via-wearable-devices-100625558","NCT07424196","Physiological Benefits From the Removal of Tracheostomy Tubes (Obtained Via Wearable Devices)","Collect Physiological Data of Patients Before and After Tracheostomy Tube Removal Using Wearable Devices to Quantify Physiological Benefits of Decannulation","RVTR1","Inclusion Criteria:\n\n* 18 years≤Age≤90 years, non-mechanically ventilated patients.\n* Tracheotomy completed, ≥48 hours since cannula placement (postoperative early edema has stabilized).\n* Patient or legal representative has provided informed consent.\n* Following our department's 2018 decannulation procedure, patients who successfully completed decannulation\n\nExclusion Criteria:\n\n* Patients with abnormal skin conditions preventing continuous wearing of monitoring devices;\n* Interruption of physiological monitoring data;\n* Poor quality of physiological monitoring data;\n* Recent (≤48 hours) major neck\u002Fupper airway surgery requiring avoidance of upper airway airflow impact.\n* Severe consciousness disorder\u002Fdelirium (RASS ≤ -3 or ≥ +2), extreme anxiety\u002Finability to cooperate.\n* Total laryngectomy or laryngo-tracheal separation.\n* Age \\\u003C18 years, Age \\> 90years.\n* Malignant tumor with an expected survival time ≤ 6 months.\n* Patients or legal representatives unable to obtain informed consent.\n* Known contraindications for tracheotomy decannulation.\n* Unable to comply with the use of wearable devices","90 Years",{"count":141,"type":23},60,"The population included in this study consists of tracheostomy patients admitted to the pulmonary department of Beijing Rehabilitation Hospital, undergoing decannulation rehabilitation treatment. After the patient is admitted, the research team evaluates whether they are suitable to enter the decannulation process. For enrolled patients, a 24-hour wearable device is worn upon admission to record physiological parameters.\n\nPatients, following clinical and rehabilitation treatment, can start using a \"speaking valve\" as soon as their condition permits. Within the first 24 hours prior to the initial use of the speaking valve, wearable devices may be utilized a second time to gather data.\n\nPatients successfully completed the decannulation process, tolerating the speaking valve for 4 hours (PEF\u002FPCF ≥ 100liters\u002Fmin).The wearable device was utilized to gather 24 hours physiological parameters for the third time within the 24 hours leading up to decannulation.\n\nPatients who underwent successful decannulation had physiological parameters collected for the forth time using wearable devices within 24 hours prior to discharge.\n\nThis study preliminarily compares the differences in physiological parameters at four time points (within 24 hours of admission, within 24 hours prior to using a speaking valve, within 24 hours prior to decannulation and within 24 hours before discharge), predicts the physiological benefits of decannulation for patients, and advocates for the concept of \"early decannulation.\" Decannulation criteria: If the patient can tolerate wearing the speaking valve continuously for 4 hours (gradually increasing the duration: 30 minutes, 1 hour, 2 hours, 4 hours), and if PEF\u002FPCF ≥ 100 liters\u002Fmin, planned removal of the tracheostomy tube can be considered.\n\nCriteria for successful decannulation: Patients who successfully completed the decannulation process and had their tubes removed, with no reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours after decannulation.",[144,29,145],"Physiological Parameters","Tracheostomy Decannulation",[147,144,29,148],"speaking valve","Tracheostomy decannulation","2026-05-30",{"date":151,"type":36},"2026-06-03",{"date":153,"type":23},"2026-06-01",{"date":155,"type":23},"2027-03-30",{"name":157,"class":43},"Bin Zhang",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":109,"phases":167,"briefSummary":168,"conditions":169,"keywords":174,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":97},"100612156","feasibility-of-wearables-in-dementia-care-in-rural-taiwan-100612156","NCT07249918","Feasibility of Wearables in Dementia Care in Rural Taiwan","Facilitating the Measurement and Treatment of the Behavioral Symptoms of Dementia (BPSD) and Understanding Caregiver Burden Using Wearable Devices in Rural Taiwan - A Dyadic Feasibility Pilot Study","Inclusion Criteria:\n\n* For participants with dementia:\n\n  1. Clinical diagnosis of probable Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD, based on established diagnostic criteria.\n  2. Presence of at least one prominent behavioral or psychological symptom of dementia (BPSD), including depression, agitation, apathy, or nighttime sleep disturbance.\n  3. Prominent is defined as:\n\n     NPI single-item score ≥ 4 (severity × frequency), or NPI-Q severity score ≥ 2, or PSQI total score ≥ 5 (if sleep disturbance is the main symptom).\n  4. Stable living arrangement or care environment for at least two weeks before enrollment.\n  5. If receiving any pharmacological or non-pharmacological treatments for BPSD, the dosage and frequency must have remained stable for at least two weeks prior to study participation.\n  6. Able and willing to provide informed consent; for those lacking decision-making capacity, consent must be obtained from a legally authorized representative.\n* For primary caregivers:\n\n  1. Adult primary caregiver of the enrolled participant.\n  2. If receiving treatment for caregiver stress, the dosage and frequency must have been stable for at least two weeks before enrollment.\n  3. Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Any medical condition that may increase risk during participation, including:\n\n  1. Retinal disease, active use of photosensitizing medications, recent ocular surgery (within 4 weeks), or photosensitivity disorders (e.g., epilepsy).\n  2. Unstable physical or mental condition deemed unsuitable by investigators, such as acute delirium or active respiratory infection (including COVID-19)",{"count":166,"type":23},20,[111],"Taiwan is becoming a super-aged society, and more older adults are living with Alzheimer's disease. Many people with Alzheimer's experience behavioral and psychological symptoms, such as agitation, sleep problems, or mood changes. These symptoms often lower their quality of life and increase stress for their family caregivers.\n\nThis study will test two wearable devices in people with Alzheimer's and their caregivers. One device, called Geneactiv, is a wristwatch that tracks daily activity and sleep. The other device, called Re-Timer, is a light therapy eyewear that may help improve sleep and mood. Researchers will look at how easy the devices are to use, whether participants are willing to wear them for several weeks, and whether the light therapy helps reduce sleep problems or caregiver stress.\n\nThe study will also compare information from questionnaires with information collected by the devices. The results may help researchers design future studies using wearable tools to better support people living with dementia and their caregivers.",[170,171,29,172,173],"Alzheimer's Dementia","Neuropsychiatric Symptoms Related to Neurodegenerative Disease","Caregiver Burden of People With Dementia","Circadian Rhythm",[175,176,177,178,179],"Wearable device","behavioural and psychological symptoms of dementia (BPSD)","Sleep","Alzheimer's dementia","Caregiver Burden","2026-02-09",{"date":182,"type":36},"2026-02-11",{"date":184,"type":36},"2025-11-18",{"date":186,"type":23},"2026-12-31",{"name":188,"class":43},"China Medical University Hospital",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":18,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":198,"studyType":24,"phases":4,"briefSummary":199,"conditions":200,"keywords":210,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":97},"100617738","smartwatch-accuracy-for-measuring-vitals-and-anxiety-before-disc-surgery-100617738","NCT07322523","Smartwatch Accuracy for Measuring Vitals and Anxiety Before Disc Surgery","Validation of Smartwatch Technology for Preoperative Monitoring of Sleep Quality, Anxiety, and Vital Signs in Patients Undergoing Disc Herniation Surgery","Inclusion Criteria:\n\n* 22 years and older\n* Currently receiving preoperative care\u002Fassessment for disc herniation surgery.\n* No history of any cardiovascular disease other than controlled hypertension.\n* Willingness to wear the smartwatch for a minimum of 8 consecutive hours during the night before surgery.\n* Ability to follow all instructions related to the smartwatch operation and data collection independently.\n* No known allergy to nickel.\n\nExclusion Criteria:\n\n* Patients who are currently receiving prescribed medication specifically for sleep in the clinical setting.\n* Refusal or unwillingness to participate in the study.\n* The participant fails to wear the smartwatch correctly or appropriately as per study instructions, leading to incomplete or unreliable data collection.","22 Years",{"count":141,"type":23},"3 Months","This study aims to verify the accuracy of blood pressure, heart rate, blood oxygen saturation, anxiety level, and sleep cycle data measurements obtained from Samsung smartwatches compared to the currently accepted method used in patients with disc herniation undergoing the preoperative period.",[201,202,203,204,205,206,207,208,29,209],"Disc Herniations","Disc Herniation, Lumbar","Cervical Disc Herniation","Preoperative Anxiety Score","Sleep Quality","Preoperative Care","Vital Signs Monitoring","Smart Watch","Surgical Nursing",[211,212,213,214,215,216,217,218],"Disc herniations","wearable devices","smart watch","vital signs monitoring","sleep quality","anxiety","surgical nursing,","preoperative","2025-12-22",{"date":221,"type":36},"2026-01-07",{"date":223,"type":36},"2025-11-01",{"date":225,"type":23},"2026-03-30",{"name":227,"class":43},"Halil Kalaycı",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":18,"minAge":236,"maxAge":52,"enrollmentInfo":237,"targetDuration":239,"studyType":24,"phases":4,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":97},"100595326","wearable-technology-and-machine-learning-for-early-detection-and-risk-assessment-of-unacceptable-toxicities-in-a-paediatric-oncology-cohort-100595326","NCT07030998","Wearable Technology and Machine Learning for Early Detection and Risk Assessment of Unacceptable Toxicities in a Paediatric Oncology Cohort","WEARABLES: Wearable Technology and Machine Learning for Early Detection and Risk Assessment of Unacceptable Toxicities in a Paediatric Oncology Cohort","WEARABLES","Inclusion Criteria:\n\n* Paediatric, adolescent or young adult diagnosis of cancer AND receiving therapy placing them at risk of infection\n* Receiving cancer treatment at The Royal Children's Hospital\n* Patients aged 5-18 years at time of the eligibility screening\n* If aged \\\u003C 16 years, parent or guardian able to provide consent\n* iPhone 8 or later (iOS must be up to date\u002Fupdated at time of enrolment)\n* At least 10MB of iPhone storage for WEARABLES app and data collection.\n* Willing and able to wear a wearable device for a period of 4 weeks (during waking hours).\n* Consent to data being shared to the WEARABLES app (owned by the research team).\n\nExclusion Criteria:\n\n* \\\u003C5 years of age.\n* \\\u003C16 years of age without guardian or parent consent.\n* Aged 16-18 and unable to provide consent.\n* Participant did not consent to wearing Apple Watch for a period of 4 weeks.","5 Years",{"count":238,"type":23},150,"4 Weeks","Data collection study to establish a predictive model of infection observed during childhood cancer therapy using data captured by wearable technology.",[242,243,244,29],"Cancer","Infection","Digital Health",[242,246,243,247,248],"Paediatric","Treatment Toxicity","Wearable Device","2025-11-14",{"date":251,"type":36},"2025-11-17",{"date":253,"type":36},"2025-10-15",{"date":255,"type":23},"2027-12",{"name":257,"class":43},"Murdoch Childrens Research Institute"]